C-TEIJ3D cell expansion, placenta-derived cell therapy, cell-based manufacturing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop an allogeneic MAIT-cell platform for targeting solid tumors.
Allogeneic MAIT platform research presented in an AACR-IO poster.
2025 AACR-IO poster on advancing the allogeneic MAIT platform for targeting solid tumors.
Investigate whether PLX-PAD can rehabilitate cocaine-induced microglial impairment and treat cocaine addiction-related pathology.
Preclinical rat-model research using placenta-derived mesenchymal-like adherent stromal cell therapy.
2025 publication listed on cocaine-induced microglial impairment and rehabilitation by PLX-PAD cell therapy.
A 2022 publication described placenta-derived mesenchymal-like adherent stromal cells as an effective cell therapy for cocaine addiction in a rat model.
Provide post-exposure prevention or treatment of hematopoietic syndrome of acute radiation syndrome after ionizing radiation exposure.
Intramuscular administration of ex vivo expanded human placenta-derived stromal cells that secrete cytokines supporting hematopoietic recovery.
2025 publication describing PLX-R18 as a radiation-associated injury countermeasure with open FDA investigational drug status for H-ARS.
Preclinical studies showed prevention and mitigation of hematopoietic acute radiation syndrome in animal models; a human Phase I bone marrow failure study supported safety and hematopoietic regeneration.
Improve incomplete hematopoietic recovery and persistent cytopenia after hematopoietic cell transplantation.
Escalating-dose Phase I study of PLX-R18 administered by multiple intramuscular injections.
2023 Phase I publication and 2025 correction in Bone Marrow Transplantation.
The Phase I study reported PLX-R18 was safe and well tolerated; blood counts increased over months, platelet and red blood cell transfusion needs declined, and effects were maintained for most measures to 12 months.
Treat critical limb ischemia in patients unsuitable for revascularization, including patients with minor tissue loss.
Intramuscular injections of placenta-derived mesenchymal-like adherent stromal cells in randomized, placebo-controlled, multicenter clinical studies.
Phase III PACE study publication for PLX-PAD in critical limb ischemia.
A randomized, controlled, multicentre, multinational Phase III study of PLX-PAD for critical limb ischemia was listed among company publications.
Investigate extracellular vesicles from therapy-grade PLX stromal cells for angiogenesis, skin regeneration, and immunomodulation.
Scalable extracellular vesicle separation using tangential flow filtration, proteomics, microscopy, in vivo skin regeneration and angiogenesis assays, and in vitro immune-cell assays.
2022 Journal of Extracellular Vesicles publication on functional corona around PLX extracellular vesicles.
PLX-EVs ameliorated human skin regeneration and angiogenesis in vivo, altered immune-cell signaling, and dose-dependently inhibited T-cell proliferation in vitro; corona removal abrogated angiogenesis.
Help intubated and mechanically ventilated COVID-19 patients recover more quickly with fewer complications.
Open-label and double-blind multicenter clinical studies of mesenchymal-like adherent stromal cells.
ClinicalTrials.gov records for multicenter COVID-19 studies.
Regenerate or treat injured gluteal or other musculature after hip arthroplasty or hip fracture surgery.
Local intramuscular PLX-PAD administration in clinical studies after total hip arthroplasty or arthroplasty for hip fracture.
ClinicalTrials.gov records evaluating efficacy, safety, and tolerability for muscle injury following arthroplasty.
Evaluate safety and clinical efficacy of PLX-PAD in subjects with intermittent claudication.
Intramuscular PLX-PAD injections using low-dose, high-dose, placebo, single-treatment, and double-treatment study arms.
ClinicalTrials.gov record for safety and efficacy study in intermittent claudication.
Grow plant, animal, and human cells efficiently and cost-effectively for cell-based products across health, food tech, agri-tech, CDMO services, and other industries.
Patented three-dimensional cell expansion platforms for cell-based manufacturing.
Company description identifies 3D cell expansion as Pluri's core platform used across health and non-pharma applications.
Treat mild to moderate knee osteoarthritis.
Placenta-derived mesenchymal-like adherent stromal cell therapy program listed in the company health pipeline.
Listed in the company pipeline as PLX-PAD for mild to moderate knee osteoarthritis.